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The widespread use and development of new nonsteroidal anti-
in£ammatories (NSAIDs) has been driven, at least in part, by the
desire to avoid collateral e¡ects on the gastric mucosa and other
tissues. The question then arises as to whether either nonselective
COX (cyclooxygenase) inhibitors or selective COX inhibitors
might have a relationship to healing in the cutaneous compart-
ment. Several previous studies have addressed these concepts
(Muscara et al, 2000; Baatar et al, 2002; Berenguer et al, 2002; Lau-
lederkind et al, 2002; Muller-Decker et al, 2002;Wilgus et al, 2003).
The availability of selective inhibitors of both key enzymes in
prostanoid biosynthesis, COX-1 and COX-2, as well as the crea-
tion of transgenic mouse strains lacking expression of COX-1,
has allowed the authors of the paper by Kampfer et al to ask ^ in
a thorough and precise fashion ^ whether and how either COX-1
or COX-2 and their principal products, PGE2 and/or PGD2,
impinge on the wound healing process in mice.
This study places a somewhat di¡erent perspective on the
question of the role of cyclooygenases in wound repair. Previous
reports have shown that COX-2 is induced in the epidermis and
other cells at the wound site (Abd-El-Aleem et al, 2001; Muller-
Decker et al, 1998; Futagami et al, 2002). COX-2 inhibition re-
sulted in a decrease in PGE2 and resurfacing in a gastric ulcer
model (Berenguer et al, 2002), but it had little or no e¡ect in a
rat sponge implant (Muscara et al, 2000). Two wound healing
studies show COX-2 inhibitors a¡ect cutaneous repair (Futagami
et al, 2002;Wilgus et al, 2003), and one report shows no signi¢cant
e¡ect of either COX-1 or COX-2 inhibition (Muller-Decker et al,
2002). However, in the present study, systemic administration of
the selective COX-2 inhibitor, celecoxib, to mouse excisional
wounds did not a¡ect either PG synthase mRNA or PGE2/D2
levels. Despite the strong induction of COX-2 at the wound site,
PGE2/D2 concentrations within the wound transiently dropped
in parallel with COX-1 expression and activity. Furthermore, it
seems clear that the principal source of prostaglandin synthase
expression and PGE2/D2 shifted to the wound margin where
COX-1 levels were unperturbed. One could presume that the in-
crease in COX-2 resulted in production of other (non-PGE2/D2)
prostanoids, such as thromboxane A2. Regardless of the synthetic
pathways a¡ected by COX-2, wound healing in the present
study was una¡ected by pharmacologic inhibition of COX-2 ac-
tivity. This result is not in complete agreement with other inves-
tigations (Futagami et al, 2002), but the models have not been
identical.
The current studies provide novel information regarding the
signi¢cance of COX-1 expression in wound healing. The authors
observed transient down-regulation of COX-1, con¢nement of
its expression to the wound periphery, and dramatic reduction of
both PG synthase and PGE2/D2 levels by either COX-1 selective
or nonselective inhibitors. This inhibition was accompanied by
reduced epithelialization and loss of granulation tissue. Impor-
tantly, the e¡ects of COX-1 inhibition were ameliorated by direct
application of PGE2. COX-1 inhibition also brought about in-
creased levels of TNF-a, a cytokine that would be expected to
impact the repair process negatively. The prediction of the study
is that selective COX-2 inhibitors are not likely to impair cuta-
neous wound healing. Based on gastric and esophageal injury
studies, however, COX-2 inhibitors can have an impact on mu-
cosal resurfacing. In the present excisional model, COX-2 may
predominantly act at the level of epithelial di¡erentiation rather
than proliferation.
While COX-2 has grabbed the spotlight over the past decade,
the functional signi¢cance of the highly expressed, constitutive
isoform, COX-1, has remained unclear. For example, epithelial
development in the kidney is dependent on COX-2 but not on
COX-1 (Komho¡ et al, 2000). The present ¢ndings add substan-
tially to our developing understanding that COX-1 likely serves
critical roles, not only for the maintenance of epithelial integrity
but healing as well. Data in the GI tract suggest the importance
of both COX-1 and COX-2 in preventing gastrointestinal ulcera-
tion. These studies now suggest an even more central role for
COX-1 in epidermal healing.
The relationship between excess in£ammation and wound
healing is a double-edged sword: chronic in£ammation, which
is typically characterized by excess and persistent neutrophil ac-
tivity, can forestall the normal healing sequence, while acute in-
£ammation appears to promote a cytokine repertoire that
exaggerates several aspects of repair including epidermal hyper-
plasia, excess angiogenesis, and ¢brosis. Mononuclear cells and
their derivatives are thought to coordinate these processes, but
other cell types can certainly be involved.With respect to the in-
£uence of in£ammation on wound quality, a recent report
of reduced scarring in murine excisions treated with a topical
COX-2 inhibitor presents a di¡erent perspective: Suppression of
wound in£ammation by COX-2 inhibition can reduce the
extent of granulation/scar tissue without compromising tensile
properties (Wilgus et al, 2003). If these ¢ndings are to be trans-
lated and borne out in human studies, it may evolve that selective
anti-in£ammatory agents can be ¢ne-tuned to suppress the im-
balances of in£ammation and consequently lead to a more ideal
healing response. Based on these preceding considerations, we
may be hopeful that selective COX-2 inhibitors rather than
NSAIDs may provide improved wound healing in the postopera-
tive setting.
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